CTLA4 and neoplasm: Similarly, we showed that miR-138 could downregulate both CTLA-4 and PD-1 to inhibit tumor-infiltrating regulatory T cells (Tregs) and in vivo administration induced tumor reduction and prolonged the survival of immune syngeneic glioma-bearing mice (20).